Nektar Therapeutics (NKTR)
66.64
-1.86 (2.72%)
Upcoming Events
Latest Headlines
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 28, 2026 4:15 PM - PR NewsWire
Nektar's atopic dermatitis drug data published in The Lancet
August 25, 2026 8:30 AM - StreetInsider
Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
August 25, 2026 8:30 AM - PR NewsWire
TD Cowen Assumes Nektar Therapeutics (NKTR) at Buy
August 22, 2026 7:54 AM - StreetInsider
JPMorgan Reinstates Nektar Therapeutics (NKTR) at Neutral
August 21, 2026 3:28 AM - StreetInsider
Form 4 NEKTAR THERAPEUTICS For: Aug 18 Filed by: Zalevsky Jonathan
August 20, 2026 7:05 PM - SEC Filing
Form 4 NEKTAR THERAPEUTICS For: Aug 18 Filed by: ROBIN HOWARD W
August 20, 2026 7:03 PM - SEC Filing
Form 144 NEKTAR THERAPEUTICS Filed by: Zalevsky Jonathan
August 18, 2026 3:58 PM - SEC Filing
Form 144 NEKTAR THERAPEUTICS Filed by: ROBIN HOWARD W
August 18, 2026 3:43 PM - SEC Filing
Form SCHEDULE 13G/A NEKTAR THERAPEUTICS Filed by: Two Seas Capital LP
August 14, 2026 4:50 PM - SEC Filing
Form S-8 NEKTAR THERAPEUTICS
August 14, 2026 4:40 PM - SEC Filing
Form SCHEDULE 13G/A NEKTAR THERAPEUTICS Filed by: BIOTECHNOLOGY VALUE FUND L P
August 14, 2026 4:20 PM - SEC Filing
Form 10-Q NEKTAR THERAPEUTICS For: Jun 30
August 14, 2026 6:10 AM - SEC Filing
Form 8-K NEKTAR THERAPEUTICS For: Aug 13
August 13, 2026 4:25 PM - SEC Filing
Nektar Therapeutics (NKTR) Tops Q2 EPS by 77c
August 13, 2026 4:21 PM - StreetInsider
Nektar Therapeutics Announces Second Quarter 2026 Financial Results
August 13, 2026 4:15 PM - PR NewsWire
Form SCHEDULE 13G NEKTAR THERAPEUTICS Filed by: VANGUARD CAPITAL MANAGEMENT LLC
July 31, 2026 10:45 AM - SEC Filing
Form SCHEDULE 13G NEKTAR THERAPEUTICS Filed by: BlackRock, Inc.
July 29, 2026 3:23 PM - SEC Filing
Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets
July 28, 2026 6:00 PM - PR NewsWire
Form 4 NEKTAR THERAPEUTICS For: Jul 24 Filed by: Zalevsky Jonathan
July 24, 2026 6:35 PM - SEC Filing
Form 4 NEKTAR THERAPEUTICS For: Jul 24 Filed by: ROBIN HOWARD W
July 24, 2026 6:35 PM - SEC Filing
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 24, 2026 4:15 PM - PR NewsWire
Canaccord Starts Nektar Therapeutics (NKTR) at Buy
July 22, 2026 5:52 AM - StreetInsider
Nektar starts Phase 3 trials for eczema drug rezpegaldesleukin
July 21, 2026 7:00 AM - StreetInsider
Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
July 21, 2026 7:00 AM - PR NewsWire
Form 4 NEKTAR THERAPEUTICS For: Jun 30 Filed by: Zalevsky Jonathan
July 2, 2026 7:07 PM - SEC Filing
Form 144 NEKTAR THERAPEUTICS Filed by: Zalevsky Jonathan
June 30, 2026 4:36 PM - SEC Filing
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 26, 2026 4:30 PM - PR NewsWire
Form 4 NEKTAR THERAPEUTICS For: Jun 16 Filed by: ROBIN HOWARD W
June 18, 2026 7:08 PM - SEC Filing
Full Article List
